- In April 2024, Development. Teva Pharmaceuticals, Inc. and Launch Therapeutics entered a clinical collaboration agreement aimed at fast-tracking the development of a dual-action asthma rescue inhaler (ICS-SABA/TEV-’248) respiratory program. This collaboration highlights a focus on bringing advanced, combined therapies to market more quickly to address patient needs in respiratory conditions
- In May 2024, Amphastar Pharmaceuticals, Inc. announced that the U.S. FDA granted approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol. This approval marks Amphastar's first generic inhalation product, offering a more accessible and cost-effective treatment option for bronchospasm, and signifies advancements in generic complex drug product manufacturing
- In May 2024, Aptar Pharma showcased its extensive portfolio of respiratory drug delivery solutions, including advancements in sustainable pressurized Metered Dose Inhalers (pMDIs) and an expanding range of connected devices for digital medicines at the Respiratory Drug Delivery (RDD) 2024 conference. This demonstrates an industry focus on sustainability and integrating digital health for enhanced patient outcomes
- In July 2023, Viatris launched Breyna inhalation aerosol, the first FDA-approved generic version of Symbicort (budesonide and formoterol fumarate dihydrate) for asthma and COPD patients in the U.S., in collaboration with Kindeva. This launch increases patient access to affordable, critical combination therapies for chronic respiratory conditions
- In January 2023, AstraZeneca announced the FDA approval of AIRSUPRA® (albuterol/budesonide) inhalation aerosol for the as-needed treatment or prevention of asthma symptoms and to help prevent sudden severe breathing problems in adults. This represents a significant advancement as the first FDA-approved anti-inflammatory rescue option for asthma, combining a SABA and an inhaled corticosteroid
